A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses.

Wilkinson, Bethanie; Patel, Kinjal S; Smith, Katherine; Walker, Robert; Wang, Chengbin; Greene, Ann M; Smith, Gale; Smith, Emily R; Gurwith, Marc; Chen, Robert T

Wilkinson, Bethanie; Patel, Kinjal S; Smith, Katherine; Walker, Robert; Wang, Chengbin; Greene, Ann M; Smith, Gale; Smith, Emily R; Gurwith, Marc; Chen, Robert T.

Affiliation

Wilkinson B; Novavax, Inc., Gaithersburg, MD, USA.
Patel KS; Novavax, Inc., Gaithersburg, MD, USA.
Smith K; Novavax, Inc., Gaithersburg, MD, USA.
Walker R; Novavax, Inc., Gaithersburg, MD, USA.
Wang C; Novavax, Inc., Gaithersburg, MD, USA.
Greene AM; Novavax, Inc., Gaithersburg, MD, USA.
Smith G; Novavax, Inc., Gaithersburg, MD, USA.
Smith ER; Brighton Collaboration, a program of the Task Force for Global Health, Decatur, GA, USA. Electronic address: bc-coordinator@taskforce.org.
Gurwith M; Brighton Collaboration, a program of the Task Force for Global Health, Decatur, GA, USA.
Chen RT; Brighton Collaboration, a program of the Task Force for Global Health, Decatur, GA, USA.

Vaccine ; 41(45): 6762-6773, 2023 10 26.

Article in En | MEDLINE | ID: mdl-37739888

Subject(s)
Key words

COVID-19 Vaccine; Coronavirus; NVX-CoV2373; Protein vaccine safety; SARS-CoV-2; Vaccine benefit/risk; Vaccine efficacy; Vaccine immunogenicity

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Adolescent / Adult / Humans Language: En Journal: Vaccine Year: 2023 Document type: Article Affiliation country: Estados Unidos Country of publication: Países Bajos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google